NMRA-335140 compared with placebo for depression
About this title
Read the official source — NCT06058013Researchers compared NMRA-335140 and placebo to find out how the approaches affected depression symptoms in people with depression.
Understand this study
What did researchers investigate?
Researchers compared NMRA-335140 and placebo to find out how the approaches affected depression symptoms in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Encino and 73 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 430
- Sponsor
- Neumora Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Brazil, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06058013
- Official title
Show the full official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Encino, United States · Garden Grove, United States · Los Alamitos, United States
55 more locations
- Newport Beach, United States
- Orange, United States
- Santa Ana, United States
- Norwalk, United States
- Bradenton, United States
- Hollywood, United States
- Homestead, United States
- Lauderhill, United States
- Maitland, United States
- Miami, United States
- Miami Lakes, United States
- Orlando, United States
- Pinellas Park, United States
- Pompano Beach, United States
- Tampa, United States
- Atlanta, United States
- Marrero, United States
- New Orleans, United States
- Baltimore, United States
- Towson, United States
- Boston, United States
- Watertown, United States
- Mankato, United States
- Princeton, United States
- Toms River, United States
- Albuquerque, United States
- Buffalo, United States
- Inwood, United States
- New York, United States
- The Bronx, United States
- Monroe, United States
- North Canton, United States
- Edmond, United States
- Oklahoma City, United States
- Philadelphia, United States
- North Charleston, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- Bellevue, United States
- Everett, United States
- Curitiba, Brazil
- Porto Alegre, Brazil
- Santa Cecília, Brazil
- São Bernardo do Campo, Brazil
- São José do Rio Preto, Brazil
- Rio de Janeiro, Brazil
- São Paulo, Brazil
- Kelowna, Canada
- Hamilton, Canada
- Markham, Canada
- Toronto, Canada
- Santiago, Chile
- Antofagasta, Chile
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared NMRA-335140 and placebo to find out how the approaches affected depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Neumora Therapeutics, Inc.
Did this study involve medication?
Yes. The study involved medication, including NMRA-335140 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
